Basic & Clinical Medicine ›› 2025, Vol. 45 ›› Issue (4): 456-464.doi: 10.16352/j.issn.1001-6325.2025.04.0456

• Original Articles • Previous Articles     Next Articles

Evaluation of chemotherapy drug efficacy using organoids model of colorectal cancer

GUO Yuehong1, ZHOU Fanqi1, WU Xi2, ZHANG Guannan3, WANG Fang1*, YU Jia1*   

  1. 1. Department of Biochemistry and Molecular Biology,Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC,Beijing 100005;
    2. Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021;
    3. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100730, China
  • Received:2025-01-15 Revised:2025-02-20 Online:2025-04-05 Published:2025-03-24

Abstract: Objective To establish human colorectal cancer(CRC) organoids and to evaluate the efficacy of chemotherapy drugs. Methods Patient-derived CRC cells were cultured to form organoids. The CRC organoids and original tissues were stained with molecular markers of CRC immunohishtochemically. CRC organoids were used to test drug sensitivity and different concentrations of chemotherapy drugs 5-fluorouracil, oxaliplatin and irinotecan were given respectively; Organoid activity before and after drug treatment was measured by 3D cell viability assay. Results The patient-derived organoids(PDO) from 5 CRC tissues were successfully established. The expression of CK20, Ki67 and Villin proteins was similar in organoids and in original tumor. The organoids retained histologcial features similar to those of the original tumors. Different PDO showed differential sensitivity to different chemotherapy drugs. Conclusions CRC-PDO can dispaly their different sensitivities to different chemotherapy drugs, and could provide valuble reference for personalized treatment for CRC patients.

Key words: colorectal cancer organoids, drug sensitivity

CLC Number: